| 杨荣明，王敏，陈婷.司库奇尤单抗联合阿维A胶囊治疗中重度斑块型银屑病的效果观察[J].实用中西医结合临床,2023,23(15):9-12 |
| 司库奇尤单抗联合阿维A胶囊治疗中重度斑块型银屑病的效果观察 |
| Observation on the Effects of Secukizumab Combined with Acitretin Capsules in the Treatment of Moderate to Severe Plaque Psoriasis |
| |
| DOI： |
| 中文关键词: 中重度斑块型银屑病 司库奇尤单抗 阿维A胶囊 炎症反应 |
| 英文关键词: Moderate to severe plaque psoriasis Secukizumab Acitretin capsules Inflammatory reaction |
| 基金项目: |
|
| 摘要点击次数: 118 |
| 全文下载次数: 62 |
| 中文摘要: |
| 目的：观察中重度斑块型银屑病应用司库奇尤单抗联合阿维A胶囊治疗的效果。方法：选取2020年1月至2022年6月江西省上犹县人民医院收治的68例中重度斑块型银屑病患者为研究对象，经双盲法随机分为对照组（n=34）与实验组（n=34）。对照组应用阿维A胶囊治疗，实验组在对照组基础上加用司库奇尤单抗治疗。观察两组治疗效果、症状改善情况、炎症反应指标、生活质量及不良反应发生率。结果：实验组治疗总有效率为94.12%，高于对照组的73.53%（P＜0.05）；用药前两组红斑、鳞屑、皮损面积及瘙痒评分对比，差异无统计学意义（P＞0.05）；用药后两组红斑、鳞屑、皮损面积及瘙痒评分均降低，且实验组低于对照组（P＜0.05）；用药前两组C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）及白介素-17（IL-17）水平对比，差异无统计学意义（P＞0.05）；用药后两组各项因子水平均降低，且实验组低于对照组（P＜0.05）；用药前两组生活质量综合评定问卷（GQOL-74）评分对比，差异无统计学意义（P＞0.05）；用药后两组GQOL-74各维度评分均升高，且实验组高于对照组（P＜0.05）；两组不良反应发生率相比，差异无统计学意义（P＞0.05）。结论：针对中重度斑块型银屑病患者应用司库奇尤单抗联合阿维A胶囊治疗效果确切，不仅有助于改善临床症状，还能减轻炎症反应，提升生活质量，安全性可靠。 |
| 英文摘要: |
| Objective: To observe the therapeutic effects of combination therapy with Secukizumab and Acitretin capsules on moderate to severe plaque psoriasis. Method: 68 patients with moderate to severe plaque psoriasis admitted to thehospital from January 2020 to June 2022 were selected as the study subjects. They were randomly divided into a control group (n=34) and an experimental group (n=34) using the double blind method. The control group was treated with Acitretin capsules, while the experimental group was treated with an additional dose of Secukizumab on top of the control group. Observe the treatment effect, symptom improvement, inflammatory response indicators, quality of life, and incidence of adverse reactions in both groups. Result: The total effective rate of the experimental group was 94.12%, which was higher than 73.53% in the control group (P＜0.05). There was no difference in erythema, scales, lesion area and itching scores between the two groups before medication (P＞0.05), but both decreased after medication. The erythema, scales, lesion area and itching scores in the experimental group were lower than those in the control group (P＜0.05). There was no difference in the levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α）and interleukin-17 (IL-17) before medication compared to both groups (P＞0.05). After medication, the levels of various factors in both groups decreased, and the experimental group was lower than the control group (P＜0.05). There was no difference in the scores of the GQOL-74 comprehensive quality of life questionnaire between the two groups before medication (P＞0.05). After medication, the scores of all dimensions of GQOL-74 in both groups increased, and the experimental group was higher than the control group (P＜0.05).There was no difference in the incidence of adverse reactions between the two groups (P＞0.05). Conclusion: The treatment of moderate to severe plaque psoriasis patients with the combination of Secukizumaband Acitretincapsules has a definite effect. It not only helps to improve clinical symptoms, but also reduces inflammatory reactions, improves quality of life, is safe and reliable, and has high clinical promotion value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
